« Previous Release | Next Release »
WILMINGTON, N.C., (March 5, 2012) - Spotlighting the quality of its clinical talent, Pharmaceutical Product Development, LLC (PPD) today announced that R&D Directions magazine has recognized a PPD scientist for his expertise in clinical research.
The magazine named Gabor Komaromy-Hiller, Ph.D., executive director, PPD global central laboratories, to its 2012 list of notable people in research and development.
"We heartily congratulate Gabor for this outstanding recognition of his expertise, teamwork and client-focused philosophy in clinical research," said Elena Logan, PPD senior vice president, global central laboratory services. "Gabor serves as a role model in delivering quality, innovation and value to support our clients' research initiatives."
PPD's global central laboratories are among the world's largest dedicated exclusively to clinical trials, with locations in Belgium, China, Singapore and the United States serving investigator sites in virtually every country where clinical research is performed.
Komaromy-Hiller and his colleagues recently delivered significant cost savings for a PPD client by developing a chromatography-based assay that measures 14 antidepressants in one analytical run, rather than employing traditional approaches using seven to 10 different analytical assays.
A native of Hungary, Komaromy-Hiller began his career as a pharmacist and earned a doctorate in analytical chemistry at the University of Idaho.
To reduce costs and increase testing efficiency, Komaromy-Hiller's initial clinical research focused on using liquid chromatography with tandem mass spectrometry detection technology for traditional biomarkers, R&D Directions noted.
That research led to a U.S. patent for determination of dicarboxylic acids, important biomarkers in vitamin B12 deficiency and inherited metabolic diseases.
A passionate believer in the power of effective teamwork, Komaromy-Hiller promotes training, team development and continual improvement of systems and processes.
"An individual cannot make a difference alone," he said. "That's why a focus on systems and teamwork is absolutely paramount to success in clinical research."
About PPD
PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 45 countries and more than 11,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about the R&D Directions' recognition, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors which could cause future results to differ materially include the following: competition in the outsourcing industry; the ability to attract, integrate and retain key personnel, including a new CEO; risks associated with and dependence on strategic relationships; rapid technological advances that make our services less competitive; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; PPD's ability to win new business; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; actual operating performance; risks associated with acquisitions and investments; compliance with drug development regulations; changes in the regulation of the drug development process; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD's estimates or views as of any date subsequent to the date hereof.
Contacts
Media:
Ned Glascock
+1 910 558 8760
ned.glascock@ppdi.com
Investors:
Luke Heagle
+1 910 558 7585
luke.heagle@ppdi.com
Delicious
Digg
Facebook
LinkedIn
Twitter